Exosomal miR-106b serves as a novel marker for lung cancer and promotes cancer metastasis via targeting PTEN

• DOI: 10.1016/j.lfs.2020.117297
• Publication Date: 2020-01-16T02:03:42Z
• Authors: Shifang Sun; Hailin Chen; Chenlei Xu; Yun Zhang; Qiaoli Zhang; Lei Chen; Qunli Ding; Zaichun Deng
• Keywords: Adult; Male; 0303 health sciences; Lung Neoplasms; PTEN Phosphohydrolase; Gene Expression; Apoptosis; Middle Aged; Exosomes; 3. Good health; Gene Expression Regulation, Neoplastic; MicroRNAs; 03 medical and health sciences; Cell Movement; Cell Line, Tumor; Lymphatic Metastasis; Biomarkers, Tumor; Humans; Female; Neoplasm Invasiveness; Neoplasm Metastasis; Aged; Cell Proliferation

As novel non-invasive tumor diagnostic biomarkers, exosomal bioactive miRNAs have received increasing attention. Herein, the aim of this study is to explore the clinical values and roles of exosomal miR106b in lung cancer. The exosomal miR-106b level was much higher in the serum of patients with lung cancer than that in healthy volunteers. Also, the exosomal miR-106b level in the lung cancer patient serum was associated with TNM stages and lymph node metastasis. Furthermore, exosomal miR-106b enhanced the migrated and invasive ability of lung cancer cells and increased the MMP-2 and MMP-9 expression. Mechanistically, exosomal miR-106b could target PTEN, and promote lung cancer cell migration and invasion. More importantly, PTEN overexpression reversed the effect of exosomal miR-106b on lung cancer cell migration and invasion. Taken together, these findings indicate that exosomal miR-106b may be a promising diagnostic biomarker and drug target for patients with lung cancer.